## 4 Conclusions  
CBG (cannabigerol), a lipophilic cannabinoid, faces challenges such as degradation and low aqueous solubility, which hinder its oral bioavailability. However, its diverse biological activities present significant commercial potential. This study investigates CNC-CTAB structures as carriers for the intestinal delivery of CBG, aiming for effective and prolonged release to enhance its biological effects. A key finding is that CNC-CTAB encapsulating CBG shows no cytotoxicity toward intestinal cells at concentrations up to 0.12 g/L, effectively reducing CBG's inherent cytotoxicity. This highlights the potential of encapsulation for safer CBG delivery. Experiments with Caco-2 cells demonstrated that encapsulated CBG significantly reduced reactive oxygen species (ROS) production induced by hydrogen peroxide, illustrating its capacity to counteract oxidative stress. Importantly, the encapsulated system exhibited enhanced ROS-reducing efficacy compared to free CBG, all while maintaining safe levels for intestinal cells. The unique receptor-mediated interactions of CBG contribute to its anti-inflammatory effects, which were not significantly altered by encapsulation. The encapsulated system effectively lowered cytokine production to levels comparable to the anti-inflammatory drug betamethasone. Furthermore, the CNC-CTAB delivery system exhibited antimicrobial properties against _Campylobacter jejuni_, underscoring its potential in addressing this pathogen and alleviating associated gastrointestinal inflammation. The slow-release profile of the encapsulated CBG under gastrointestinal conditions ensures prolonged exposure of the bioactive compound to intestinal cells and pathogens, enhancing its biological functions. Given the critical role of inflammation, redox imbalance, and the involvement of _Campylobacter jejuni_ in intestinal inflammatory diseases, our findings emphasize the potential of this encapsulation strategy to improve CBG's efficacy in combating such conditions while addressing cytotoxicity concerns. This study is the first to explore the biocompatibility, biological capabilities, and gastrointestinal release profile of CNC-CTAB delivery systems encapsulating CBG. The results point to the promise of encapsulated CBG, particularly its receptor-mediated effects, for applications targeting intestinal inflammation and microbial infections, enabling safer administration at higher doses.  
Writing--original draft preparation: F.C. Writing--review and editing: O.L.R., J.C.F., C.F.P., A.B.R., P.M.C., R.F., E.M., D.T.-V., L.L.P., L.M.R.-A. and M.E.P. Conceptualization: O.L.R., J.C.F. and F.C. Supervision: O.L.R. and J.C.F. Validation: O.L.R., J.C.F. and M.E.P. Methodology: J.C.F., O.L.R., D.T.-V., L.L.P., A.L.F., L.M.R.-A. and F.C. Resources: O.L.R., J.C.F. and M.E.P. Project administration: M.E.P. All authors have read and agreed to the published version of the manuscript.  
Project co-financed by the European Regional Development Fund (ERDF), through the Operational Program for Competitiveness and Internationalization (POCI) supported by Amyris Bio Products Portugal, Unipessoal Ltd. and Escola Superior de Biotecnologia--Universidade Catolica Portuguesa through the Alchemy project \"Capturing High Value from Industrial Fermentation Bio Products\" (POCI-01-0247-FEDER-027578). We would also like to thank the scientific collaboration under the FCT project UID/Multi/50016/2020.  
**Informed Consent Statement:** Not applicable.  
**Data Availability Statement:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.  
**Acknowledgments:** The authors gratefully thank [PERSON] and the Project TEX4 WOUNDS (POCI-01-0247-FEDER-047029), financed under the Incentive System for Research and Technological Development, R&DT Projects, in co-promotion (Notice SI/17/2019) for the SEM.  
**Conflicts of Interest:** The authors declare no conflicts of interest.